Organigram Global (STU:0OG) Stock Based Compensation: €2.2 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0OG Organigram Global Inc STU:0OG
60 GF Score
Price €0.79
GF Value €1.54
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Organigram Global Stock Based Compensation?

Organigram Global STU:0OG -6.86% 60 Stock Based Compensation is €2.2 Mil as of Mar. 2026. GuruFocus rates STU:0OG with a GF Score™ of 60/100 and a GF Value™ of €1.54 (Possible Value Trap). The stock has 1 warning sign investors should review.

Organigram Global's Stock Based Compensation for the three months ended in Mar. 2026 was €0.5 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €2.2 Mil.

Organigram Global Stock Based Compensation Related Terms

Organigram Global Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Organigram Global's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organigram Global Stock Based Compensation Chart

Organigram Global Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Sep24 Sep25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.98 2.63 3.92 4.78 2.60

Organigram Global Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.64 0.58 0.48 0.46
STU:0OG
60GF Score
Organigram Global Inc STU:0OG
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organigram Global Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.2 Mil.

What does a Stock Based Compensation of €2.2 Mil mean?
Organigram Global (STU:0OG) has a Stock Based Compensation of €2.2 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Organigram Global and its competitors.
Is Organigram Global's Stock Based Compensation too high?
Organigram Global's current Stock Based Compensation is €2.2 Mil. Overall, Organigram Global has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Stock Based Compensation compare to ZTS and UTHR?
Organigram Global's Stock Based Compensation of €2.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Organigram Global and its competitors. Organigram Global's current Stock Based Compensation is €2.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.79 — trading 48.8% below its estimated fair value. The current Stock Based Compensation is €2.2 Mil. Organigram Global's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Stock Based Compensation is €2.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organigram Global (STU:0OG) Overvalued in 2026?

Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued. The current stock price of €0.79 is trading 48.8% below its estimated GF Value™ of €1.54. GuruFocus considers Organigram Global to be Possible Value Trap.

Key valuation signals for STU:0OG:

  • Stock Based Compensation: €2.2 Mil
  • GF Value™: €1.54 vs. price of €0.79 (48.8% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organigram Global Business Description

Other Exchanges OGI:USAOGI:Canada
Address 145 King Street West, Suite 1400, Toronto, ON, CAN, M5H 1J8
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
60GF Score

Get the complete analysis for STU:0OG

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.54
GF Value